Core Viewpoint - The announcement from Yirui Technology indicates that shareholders Tianjin Sequoia and Beijing Sequoia plan to reduce their holdings through block trading, which may impact the stock's liquidity and market perception [1] Shareholder Holdings - Tianjin Sequoia holds 11.7859 million shares, representing 5.89% of the total share capital [1] - Beijing Sequoia holds 5.5473 million shares, representing 2.77% of the total share capital [1] Planned Share Reduction - The shareholders intend to reduce their holdings by up to 4.0044 million shares, which is not more than 2% of the total shares outstanding [1] - The reduction period is set from August 15, 2025, to November 14, 2025 [1] Previous Share Reduction - The two shareholders previously reduced their holdings by 2% (2.8558 million shares) between September 30, 2024, and November 1, 2024 [1] - The reduction price range for the previous transaction was between 113.42 and 123.03 yuan per share [1]

Core Points - The company has received approval from the China Securities Regulatory Commission (CSRC) for the issuance of A-shares to specific investors [1] - The approval is valid for 12 months from the date of registration [1] - The company is required to adhere to the submitted documents and issuance plan during the stock issuance process [1] Summary by Sections - **Approval Details** - The CSRC has issued a document approving the company's application for stock issuance to specific investors [1] - The approval mandates strict compliance with the submitted application documents and issuance plan [1] - **Regulatory Compliance** - The company must report any significant events to the Shanghai Stock Exchange from the date of approval until the completion of the issuance [1] - **Board Responsibilities** - The company's board will handle the issuance matters within the stipulated timeframe and fulfill information disclosure obligations [2]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-048 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于 2024 年度向特定对象发行 A 股股票申请 获得中国证券监督管理委员会同意注册批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奕瑞电子科技集团股份有限公司（以下简称"公司"）于近日收到中国证券 监督管理委员会出具的《关于同意上海奕瑞光电子科技股份有限公司向特定对象 发行股票注册的批复》（证监许可〔2025〕1495 号）（以下简称"批复文件"），批 复文件内容如下： 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送上海证券交易所的申报文件和发行方案 实施。 三、本批复自同意注册之日起 12 个月内有效。 四、自同意注册之日起至本次发行结束前，你公司如发生重大事项，应及时 报告上海证券交易所并按有关规定处理。 公司董事会将按照上述批复文件和相关法律法规的要求以及 ...

Company Overview - Yirui Technology's closing price on July 11 was 88.55 yuan, down 1.01%, with a rolling PE ratio of 37.80 times and a total market value of 17.729 billion yuan [1] - The company ranks 77th in the medical device industry, which has an average PE ratio of 52.06 times and a median of 37.22 times [1] - As of the first quarter of 2025, 47 institutions held shares in Yirui Technology, including 39 funds, with a total holding of 82.5452 million shares valued at 9.443 billion yuan [1] Business Operations - Yirui Technology focuses on the research, production, sales, and service of digital X-ray detectors, high-voltage generators, combination ray sources, and tubes [1] - The main product lines include the universal series, dental series, mammography series, radiotherapy series, industrial series, high-voltage generators, and combination ray sources [1] Financial Performance - In the first quarter of 2025, Yirui Technology reported revenue of 482 million yuan, a year-on-year decrease of 1.92%, while net profit was 143 million yuan, an increase of 2.74% [1] - The sales gross margin for the company was 48.92% [1]

Investment Rating - The report maintains a "Buy" rating for the company [6][20]. Core Views - The company is a leading global supplier of X-ray core components and solutions, with a diversified downstream distribution. The recovery in downstream medical, dental, and industrial sectors since 2025 is promising, and new products like CT tubes and silicon-based OLED microdisplay backplanes are expected to have significant growth potential [1][2]. - The company has announced an investment of up to RMB 1.8 billion for a silicon-based OLED microdisplay backplane production project, which is anticipated to add a capacity of 5,000 units per month [3][15]. - There is substantial domestic replacement potential for core components like CT tubes, with an estimated market space of RMB 1 to 5 billion due to the ongoing anti-dumping investigations against imports from the US and India [4][20]. Summary by Sections Financial Performance - The company expects a revenue decline of 2% in 2024, primarily due to poor downstream conditions, but anticipates a recovery in 2025 with a projected revenue increase of 17.18% [2][10]. - The forecasted net profit for 2025-2027 is RMB 5.9 billion, RMB 8.5 billion, and RMB 11.0 billion, representing year-on-year growth rates of 26%, 46%, and 29% respectively [5][19]. Revenue Breakdown - The detector segment is expected to grow at rates of 16%, 19%, and 19% from 2025 to 2027, with a recovery in demand from the medical and dental sectors [12][17]. - The core components segment is projected to see revenue growth of 43%, 39%, and 28% over the same period, driven by advancements in high-voltage generators and ray sources [13][17]. - The solutions and technical services segment is anticipated to grow significantly, with expected revenues of RMB 350 million, RMB 500 million, and RMB 700 million from 2025 to 2027 [14][17]. Valuation - The target price for the company is set at RMB 132, based on a price-to-earnings (PE) ratio of 45 times for 2025, reflecting a significant adjustment from previous estimates due to overall market conditions [5][20]. - The company's market capitalization is approximately RMB 17.36 billion, with a closing price of RMB 86.70 as of July 2, 2025 [7][10].

Group 1 - The core viewpoint of the news is that Yirui Technology's stock performance and financial metrics indicate a stable position within the medical device industry, despite a slight decline in revenue [1] - As of July 1, Yirui Technology's closing price was 88.5 yuan, with a PE ratio of 37.78 times and a total market capitalization of 17.719 billion yuan [1] - The average PE ratio for the medical device industry is 51.70 times, with a median of 37.36 times, positioning Yirui Technology at the 77th rank within the industry [1][2] Group 2 - Yirui Technology reported a revenue of 482 million yuan for Q1 2025, reflecting a year-on-year decrease of 1.92%, while net profit was 143 million yuan, showing a year-on-year increase of 2.74% [1] - The company's gross profit margin stands at 48.92% [1] - As of March 31, 2025, Yirui Technology had 5,745 shareholders, a decrease of 883 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-047 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于可转债转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 累计转股情况：截止2025年6月30日，"奕瑞转债"累计有人民币13,275,000 元已转换为奕瑞电子科技集团股份有限公司（以下简称"公司"）股票，转股数量 为57,686股，占"奕瑞转债"转股前公司已发行股份总额的0.0567%； 未转股可转债情况：截止2025年6月30日，"奕瑞转债"尚未转股的可转债 金额为1,421,735,000元，占"奕瑞转债"发行总量的99.0749%； 本季度转股情况：自2025年4月1日起至2025年6月30日，"奕瑞转债"共有 人民币1,000元已转换为公司股票，转股数量为6股，占"奕瑞转债"转股前公司已 发行股份总额的0.0000%。 一、可转债发行上市概况 经中国证券监 ...

Overview - The report discusses the share transfer of Yirui Electronic Technology Group Co., Ltd. (Yirui Technology) by its shareholder Hainan Heyi Investment Co., Ltd. to specific institutional investors through a price inquiry method before the company's initial public offering (IPO) on the Sci-Tech Innovation Board [1][8]. Share Transfer Details - The maximum number of shares to be transferred in this inquiry is 6,122,448 shares, which represents 3.06% of the total share capital of Yirui Technology as of June 20, 2025 [1][6]. - Hainan Heyi holds 34.31% of the shares prior to the IPO [1]. Pricing Mechanism - The price floor for the share transfer is set at no less than 70% of the average trading price of Yirui Technology's shares over the 20 trading days preceding June 20, 2025 [2]. - The final transfer price is determined through a competitive bidding process, with a final price set at 75.86 CNY per share, leading to a total subscription amount of approximately 464.45 million CNY [6][7]. Participation and Allocation - A total of 95 institutional investors were invited to participate in the inquiry, including 18 fund management companies, 14 securities firms, and 49 private fund managers [5]. - The final allocation of shares was made to 22 institutional investors, with the total number of shares allocated being 6,122,448 [6][7]. Compliance and Verification - The inquiry transfer process was verified to be legal and compliant with relevant regulations, including the Company Law and Securities Law of the People's Republic of China [8][14]. - Both the transferor and transferee were confirmed to meet the qualifications required by the inquiry transfer guidelines [10][13].

Summary of Key Points Core Viewpoint - The report details the results of a share transfer by Hainan Heyi Investment Co., Ltd., which sold 6,122,448 shares of Yirui Technology at a price of 75.86 yuan per share, reducing its stake from 8.91% to 5.85% without affecting the control of the company [1][2][3]. Group 1: Transfer Details - The transfer price was set at 75.86 yuan per share for a total of 6,122,448 shares [1][3]. - Hainan Heyi's shareholding decreased from 8.91% to 5.85%, resulting in a total of 11,721,318 shares held post-transfer [2][3]. - The transfer does not lead to any change in the company's controlling shareholder or actual controller [1][4]. Group 2: Transferor Information - Hainan Heyi Investment Co., Ltd. is identified as a significant shareholder, holding more than 5% of the company's shares, but is not the controlling shareholder [1][2]. - There are no concerted action relationships associated with the transferor [1][2]. Group 3: Transfer Process - The transfer process involved a price negotiation based on the company's funding needs and was conducted through a fair and transparent inquiry process [3][5]. - A total of 35 valid subscription bids were received from institutional investors, with 22 investors ultimately allocated shares [3][5].

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-046 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 1%的提示性公告 股东海南合毅投资有限公司保证向奕瑞电子科技集团股份有限公司提供的信息 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完 整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 奕瑞电子科技集团股份有限公司（以下简称"公司"、"奕瑞科技"）控股股 东、实际控制人不参与本次询价转让。 本次转让不会导致公司控股股东、实际控制人发生变化。 转让方海南合毅持股比例由8.91%增加至5.85%。 一、 转让方情况 (一) 转让方基本情况 截至 2025 年 6 月 20 日，转让方所持公司首发前股份的数量、占总股本比例情 况如下： | 序号 | 股东名称 | 持股数量（股） | 持股占总股本比例 | | --- | --- | --- | --- | | 1 | 海南合毅 ...